Posted by Michael Wonder on 06 Jan 2020
ICER posts draft scoping document for the assessment of treatments for beta thalassaemia
6 January 2020 - Document open to public comment until 27 January 2020.
The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value treatments for LentiGlobin (Bluebird Bio) and luspatercept-aamt (Reblozyl, Acceleron Pharma Inc. and Bristol-Myers Squibb/Celgene) for the treatment of beta thalassaemia.
LentiGlobin is an investigational gene therapy currently marketed in Europe under the brand name Zynteglo; an FDA decision regarding potential US approval is expected by late 2020. Luspatercept-aamt was approved by the FDA in November 2019.
